Virtual ACC: Caravaggio study confirms noninferiority of apixaban to heparin for treatment of cancer-associated...
It has been found that oral apixaban is noninferior to subcutaneous dalteparin for the treatment of cancer-related venous thromboembolism (VTE), as revealed by Giancarlo...
Virtual ACC: Rivaroxaban demonstrates superiority over enoxaparin for prevention of VTE after moderate risk...
Results of PRONOMOS, a randomised, controlled, noninferiority trial, have shown rivaroxaban to be more effective than enoxaparin in the prevention of major venous thromboembolic...
COVID-19: European Commission looking to postpone new MDR by one year
During a Q&A section of a European Commission (EC) college meeting on 25 March, EC spokesperson Stefan de Keersmaecker stated that the commission were looking to...
Adapt clinical studies to alleviate impact of pandemic
A viewpoint in the Journal of the American Medical Association (JAMA) has offered potential solutions to modifying ongoing randomised clinical trials during the COVID-19 pandemic. It...
